Effective Outsourcing of Clinical Pharmacology Studies in Europe

John Horkulak
Executive Director,
Eurasian External Clinical Study Operations
Key Questions

- Do clinical pharmacology studies require a different outsourcing model than larger late stage clinical studies?
- Are new outsourcing models needed for multi-site patient studies that require specialized clinical pharmacology services?
- What role will Europe have to play in early clinical research?
- Can strategic partnerships work to help keep up with the changing needs of early clinical research?
Clinical Pharmacology Impact Areas in Drug Development

**IND Enabling (support IND/CTA)**
- Toxicokinetics
- Allometric Scaling
- PK/PD Modeling
- Novel Biomarker Development
- Microdosing AMS (Phase 0)

**IND/C4TA**
- FIH to CPoC (support go/no go decisions)
  - SAD – safety/PK
  - MAD – safety/PK
  - Pilot Food Effect - PK
  - Elderly – safety/PK
  - Robust Cardiac Safety
  - Absolute BA (Microtacer - AMS)
  - Drug Metabolizing Enzyme Probes or Genotyping on PK
  - Early Metabolic Profile (Microtracer – AMS)
  - First-in-Patient - Signal of Effect

**Phase I/IIb/IIa**

**FIH to CPoC**

**NDA Enabling (support product labeling)**
- Drug-Drug Interactions (DDI)
- Hepatic and Renal Insufficiency on PK
- Thorough QTc (TQT)
- Radiolabeled ADME (mass balance)
- Market-image Bioequivalence (BE)
- PK or PK/PD in Special Populations
- PK or PK/PD in Pediatric Populations
- Population PK or PK/PD from Pivotal Efficacy or Safety Studies

**NDA/MAA**
- Phase IIb / III

**Product Extension (support new indications)**
- PK in New Patient Populations
- BE New Formulations
- BE Generics
- Population PK

**sNDA/ANDA (US)**
- IND/CTA
Clinical Pharmacology Studies Different From Confirmatory Clinical Trials

Clinical Pharmacology Phase I & IIa
- Small number of participants
- Few sites, usually single geography
- High density sampling
- Sampling logistics critical
- Specialized units with participant confinement capabilities
- Focus on “Proof-of-Presence”, “Proof-of-Mechanism”, “Proof-of-Concept” and specific product labeling needs.
- €€

Phase II/III Studies
- Large numbers of participants
- Many sites, many countries and geographies
- Low density sampling
- Study logistics critical
- Hospital or outpatient clinic settings
- Focus on pivotal efficacy and safety for regulatory approval and major product labeling claims
- €€€€€€€
Why healthy participants in Phase I?

- Provide more resilient human population if adverse events occur
  - TeGenero (2006). Starting dose: 1/500 NOAEL, 4/6 multi-organ failure in healthy male participants. What if they were patients?
- Clinical development should proceed with an incremental increase in clinical risk
  - Traditional Approach:
    Healthy participants (Phase I) → small group of patients (Phase II) → larger groups of patients (Phase III) → general patient population
What’s Driving Change in Early Clinical Studies

- Fail fast in Phase I
  - More information needed for early drug development decisions
- Clinical pharmacology studies becoming more complex
  - Inclusion of patient cohorts
  - More biomarkers, more sampling
    - Sampling logistics challenges
  - Fusion and adaptive designs
  - More biologic drug candidates – immunogenicity
  - Earlier robust cardiac safety assessment
What can we learn from patients?

- Is the safety profile different in patients?
  - Consider the indication
  - Comorbidities?
  - Preclinical signals for concern?
- Is drug distribution or exposure potentially different in patients?
  - Drug metabolized or excreted by liver?
  - Drug eliminated by kidney?
- Can we get a signal (hint) of efficacy?
Signal or hint of efficacy?

- What endpoints will be used?
  - Sensitivity and variability of assessment
- Will the early clinical research study be powered to see a difference?
- What will you do with the results (if not adequately powered)?
  - Issue a press release?
    - Kill the program?
    - Move forward?
- Biomarkers
  - Signal of target engagement
  - Signal to verify mechanism
What’s Changing at Clinical Pharmacology Units

- R&D cost cutting forcing closure of in-house clinical pharmacology units at major pharma companies
- Private clinical pharmacology clinics or hybrid academic-CRO clinical pharmacology units becoming experts in innovation around robust execution
  - Hiring ex-pharma expertise
  - Building platforms for innovative technologies that provide better data, faster
  - Expertise evolves from broad experience to many situations (pay for “minds” as well as “hands”)
- Global digital communications
  - Expectation of real-time data sharing and rapid digital analysis
  - Deploying smart devices in study recruitment, data capture and oversight
The Need for Global Clinical Pharmacology Unit Networks

- Most patient needs in early clinical research cannot be met by a single center
- Need to evolve similar partnering and alliance models among groups of clinical pharmacology units
  - Share patient recruiting, costs and revenues
  - Work to same quality standards (undergo common systems QA audits)
  - Valued professional relationship among PIs and/or centers
  - Coordinated through a group (CRO) which can also bring in other study services that the sponsor would need (protocol preparation, bioanalysis, PK, DM and stats, CSR preparation)
Strategic Outsourcing Phase I & Ila Studies

Benefits to Drug Developer
- Tap into expertise at specialized clinical pharmacology sites
- Benefit from growing access to specific patient populations
- Drive favorable pricing by guaranteeing volume of work to one or two suppliers
- Build trusting relationships among partnering scientific and medical staffs

Challenges for Clinical Pharmacology Services Provider
- Strategic outsourcing means different things to different drug developers
  - *Fit and philosophy on outsourcing is important*
- Trust doesn’t happen overnight
  - *Builds with commitment and gradual build up of experience*
- Managing “nice-to-have” additions to protocols that have been priced to a basic economical design
- Managing mergers, changes in management and downsizing at sponsor company
Evolution to Strategic Partnership

Transaction

- Tactical selling
- Responsive to requests

Preferred Supplier

- Master Service Agreements in place
- Core team established
- Building collaborative mechanisms
- Developing full understanding of client’s internal and external needs

Partnership

- Incorporating client into strategic planning
- Assigning dedicated relationship management
- Making directed investments
- Building strong collaborative mechanisms

Strategic Alliance

- Sharing common goals and objectives
- Engaging in joint strategic planning
- Relationship-based structure
- Making open-ended agreements
- New business forms

Increasing Mutual Trust and Shared Risk

Source: Modern Drug Discovery (3/00), Goldman Sachs Research
Effective Partnerships Leverage Both Scientific and Operational Expertise From Each Partner
Example of a Working Partnership

- Major Pharma client
  - Celerion had several years experience as a preferred provider among several other CROs
- Client required two or three strategic partners
  - Celerion selected as one of these after extensive evaluation process
- Novel approach to pricing specific study designs
  - Developed standard cost structure, with “a la carte” menu for optional additions
- Maintain simplicity while expanding and improving study design
  - Cost containment for client and increased study volume for Celerion
- Trust established and partnership expanded
  - Innovative partnering model developed to leverage the strengths of both organizations with elements of shared risk
- Required commitment by senior leaders on both sides
- Recognized that trust takes time to develop between both parties and evolved the expectations of partnership accordingly
Conclusions

- Intrinsic differences between clinical pharmacology and late phase studies which need to be considered during the outsourcing process
- Build network of specialty clinics to outsource studies
  - Collaboration with experienced clinical pharmacology CRO can speed up multi-site early phase studies in patients
- Early phase clinical research is a global business
  - Europe, with its expertise in clinical pharmacology and access to patients, will have an important role to play
- Strategic partnerships can be very beneficial if both partners truly respect what each other brings to the relationship, and there is patience to allow these partnerships to evolve over time
Effective Outsourcing of Clinical Pharmacology Studies in Europe

John Horkulak
Executive Director,
Eurasian External Clinical Study Operations